Literature DB >> 14510025

The cost effectiveness of hepatitis immunization for US college students.

R Jake Jacobs1, Sammy Saab, Allen S Meyerhoff.   

Abstract

Hepatitis B immunization is recommended for all American children, and hepatitis A immunization is recommended for children who live in areas with elevated disease rates. Because hepatitis A and B occur most commonly in young adults, the authors examined the cost effectiveness of college-based vaccination. They developed epidemiologic models to consider infection risks and disease progression and then compared the cost of vaccination with economic, longevity, and quality of life benefits. Immunization of 100,000 students would prevent 1,403 acute cases of hepatitis A, 929 cases of hepatitis B, and 144 cases of chronic hepatitis B. Hepatitis B vaccination would cost the health system $7,600 per quality-adjusted life year (QALY) gained but would reduce societal costs by 6%. Hepatitis A/B vaccination would cost the health system dollar 8,500 per QALY but would reduce societal costs by 12%. Until childhood and adolescent vaccination can produce immune cohorts of young adults, college-based hepatitis immunization can reduce disease transmission in a cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510025     DOI: 10.1080/07448480309596355

Source DB:  PubMed          Journal:  J Am Coll Health        ISSN: 0744-8481


  12 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Immunization needs of chronic liver disease patients seen in primary care versus specialist settings.

Authors:  R Jake Jacobs; Allen S Meyerhoff; Sammy Saab
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

3.  Measuring the value of public health systems: the disconnect between health economists and public health practitioners.

Authors:  Peter J Neumann; Peter D Jacobson; Jennifer A Palmer
Journal:  Am J Public Health       Date:  2008-10-15       Impact factor: 9.308

4.  Doing Good with Good OR: Supporting Cost-effective Hepatitis B Interventions.

Authors:  David W Hutton; Margaret L Brandeau; Samuel K So
Journal:  Interfaces (Providence)       Date:  2011-05       Impact factor: 1.434

5.  Too much of a good thing? When to stop catch-up vaccination.

Authors:  David W Hutton; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2013-07-15       Impact factor: 2.583

6.  Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Authors:  Yuanxi Jia; Li Li; Fuqiang Cui; Dongliang Zhang; Guomin Zhang; Fuzhen Wang; Xiaohong Gong; Hui Zheng; Zhenhua Wu; Ning Miao; Xiaojin Sun; Li Zhang; Jingjing Lv; Feng Yang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.

Authors:  David W Hutton; Samuel K So; Margaret L Brandeau
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

8.  Cost-effectiveness analysis of behavioral interventions to improve vaccination compliance in homeless adults.

Authors:  Barbara Greengold; Adeline Nyamathi; Gerald Kominski; Dorothy Wiley; Mary Ann Lewis; Felicia Hodge; Mendel Singer; Brennan Spiegel
Journal:  Vaccine       Date:  2008-11-27       Impact factor: 3.641

9.  Disease burden of chronic hepatitis B among immigrants in Canada.

Authors:  William W L Wong; Gloria Woo; E Jenny Heathcote; Murray Krahn
Journal:  Can J Gastroenterol       Date:  2013-03       Impact factor: 3.522

Review 10.  Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Authors:  Andrea M Anonychuk; Andrea C Tricco; Chris T Bauch; Ba' Pham; Vladimir Gilca; Bernard Duval; Ava John-Baptiste; Gloria Woo; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.